Paul Tudor Jones Alaunos Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.04 - $322.5 $303,708 - $94.2 Million	-292,027 Reduced 88.12%	39,374 $68,000
Q4 2021 Feb 14, 2022	BUY	$1.09 - $1.89 $131 - $228	121 Added 0.04%	331,401 $361,000
Q3 2021 Nov 15, 2021	BUY	$1.44 - $2.73 $402,023 - $762,169	279,183 Added 535.89%	331,280 $603,000
Q2 2021 Aug 16, 2021	BUY	$2.63 - $3.67 $137,015 - $191,195	52,097 New	52,097 $138,000
Q1 2021 May 17, 2021	SELL	$2.82 - $5.6 $766,399 - $1.52 Million	-271,773 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$2.09 - $3.09 $149,963 - $221,716	-71,753 Reduced 20.89%	271,773 $685,000
Q3 2020 Nov 16, 2020	BUY	$2.39 - $3.43 $679,345 - $974,960	284,245 Added 479.49%	343,526 $866,000
Q2 2020 Aug 14, 2020	SELL	$2.2 - $3.71 $148,629 - $250,643	-67,559 Reduced 53.26%	59,281 $194,000
Q1 2020 May 15, 2020	BUY	$1.9 - $4.98 $240,996 - $631,663	126,840 New	126,840 $311,000
Q1 2018 May 15, 2018	SELL	$3.46 - $5.14 $55,560 - $82,538	-16,058 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$4.0 - $6.54 $135,220 - $221,084	-33,805 Reduced 67.8%	16,058 $66,000
Q3 2017 Nov 14, 2017	BUY	$4.99 - $6.57 $248,816 - $327,599	49,863	49,863 $306,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.